Urinary acylcarnitines in a patient with neonatal multiple acyl-CoA dehydrogenation deficiency, quantified by a carboxylic acid analyzer with a reversed-phase column.
A quantitative analysis for urinary acylcarnitines in a patient with neonatal multiple acyl-CoA dehydrogenation deficiency is described. This method (liquid chromatography) can quantify twelve acylcarnitines including glutarylcarnitine and 3 isomeric acylcarnitines (butyryl-1, valeryl- and octanoylisomer) in urine. Before and up to the 15th hour of DL-carnitine therapy, isovalerylcarnitine was the largest single component existing in urinary acylcarnitines. Its excretion increased approximately 10 times within 1 day of DL-carnitine therapy. However, the acetyl-, the isobutyryl- and the butyrylcarnitine values increased gradually. From the 8th day of the therapy, the isobutyrylcarnitine value exceeded the isovalerylcarnitine. The patient's dominant urinary specific acylcarnitine derived from amino acids oxidation deficiency was changed from isovalerylcarnitine(leucine) to isobutyrylcarnitine(valine) during the early period of DL-carnitine therapy. Glutarylcarnitine was a minor component in the urine. Its degree of increase was as small as that of octanoylcarnitine. 2-Methylbutyrylcarnitine and propionylcarnitine were not detected.
Kidouchi
K
K
Department of Pediatrics, Nagoya City Higashi General Hospital, Japan.
Niwa
T
T
Nohara
D
D
Asai
K
K
Sugiyama
N
N
Morishita
H
H
Kobayashi
M
M
Wada
Y
Y
D042964:Acyl-CoA Dehydrogenase; D002331:Carnitine / Q000031:analogs & derivatives* / Q000652:urine; D002845:Chromatography; D044943:Fatty Acid Desaturases / Q000172:deficiency*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D013058:Mass Spectrometry; D008661:Metabolism, Inborn Errors / Q000201:enzymology / Q000652:urine*
D044943:Fatty Acid Desaturases; D042964:Acyl-CoA Dehydrogenase; D002331:Carnitine